1249 related articles for article (PubMed ID: 23837640)
21. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.
Liga M; Triantafyllou E; Tiniakou M; Lambropoulou P; Karakantza M; Zoumbos NC; Spyridonidis A
Biol Blood Marrow Transplant; 2013 Jan; 19(1):75-81. PubMed ID: 22871557
[TBL] [Abstract][Full Text] [Related]
22. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
Krishnamurthy P; Potter VT; Barber LD; Kulasekararaj AG; Lim ZY; Pearce RM; de Lavallade H; Kenyon M; Ireland RM; Marsh JC; Devereux S; Pagliuca A; Mufti GJ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):562-8. PubMed ID: 23266740
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy of donor lymphocyte infusion in patients after different types of allogeneic hematopoietic stem cell transplantation].
Slesarchuk OA; Babenko EV; Semenova EV; Bondarenko SN; Éstrina MA; Morozova EV; Paina OV; Vavilov VN; Smirnov BI; Zubarovskaia LS; Afanas'ev BV
Ter Arkh; 2013; 85(7):26-33. PubMed ID: 24137944
[TBL] [Abstract][Full Text] [Related]
24. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
[TBL] [Abstract][Full Text] [Related]
25. Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
Tan Y; Du K; Luo Y; Shi J; Cao L; Zheng Y; Zheng G; Zhao Y; Ye X; Cai Z; Huang H
Transfusion; 2014 Jun; 54(6):1493-500. PubMed ID: 24372162
[TBL] [Abstract][Full Text] [Related]
26. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
Huang X; Liu D
Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
[TBL] [Abstract][Full Text] [Related]
27. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.
Nordlander A; Mattsson J; Ringdén O; Leblanc K; Gustafsson B; Ljungman P; Svenberg P; Svennilson J; Remberger M
Biol Blood Marrow Transplant; 2004 Mar; 10(3):195-203. PubMed ID: 14993885
[TBL] [Abstract][Full Text] [Related]
28. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
[TBL] [Abstract][Full Text] [Related]
29. Haploidentical/mismatched hematopoietic stem cell transplantation without in vitro T cell depletion for T cell acute lymphoblastic leukemia.
Wang Y; Liu DH; Xu LP; Liu KY; Chen H; Chen YH; Han W; Zhang XH; Huang XJ
Biol Blood Marrow Transplant; 2012 May; 18(5):716-21. PubMed ID: 21924223
[TBL] [Abstract][Full Text] [Related]
30. Superior survival of unmanipulated haploidentical hematopoietic stem cell transplantation compared with chemotherapy alone used as post-remission therapy in adults with standard-risk acute lymphoblastic leukemia in first complete remission.
Yan CH; Jiang Q; Wang J; Xu LP; Liu DH; Jiang H; Chen H; Zhang XH; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1314-21. PubMed ID: 24747334
[TBL] [Abstract][Full Text] [Related]
31. Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.
Hamad N; Shanavas M; Michelis FV; Uhm J; Gupta V; Seftel M; Kuruvilla J; Lipton JH; Messner HA; Kim DD
Am J Hematol; 2015 May; 90(5):392-9. PubMed ID: 25615933
[TBL] [Abstract][Full Text] [Related]
32. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
33. Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant.
Thoma MD; Huneke TJ; DeCook LJ; Johnson ND; Wiegand RA; Litzow MR; Hogan WJ; Porrata LF; Holtan SG
Biol Blood Marrow Transplant; 2012 Apr; 18(4):600-7. PubMed ID: 21843495
[TBL] [Abstract][Full Text] [Related]
34. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.
Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS
Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882
[TBL] [Abstract][Full Text] [Related]
35. Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study.
Wang Y; Liu DH; Fan ZP; Sun J; Wu XJ; Ma X; Xu LP; Liu KY; Liu QF; Wu DP; Huang XJ
Clin Transplant; 2012; 26(4):635-43. PubMed ID: 22515260
[TBL] [Abstract][Full Text] [Related]
36. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.
Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; Moreno-Lafont M; García-Latorre E; Ramírez-Sanjuan E; Montiel-Cervantes L; Tripp-Villanueva F; García-León LD; Ayala-Sánchez M; Rosas-Cabral A; Aviña-Zubieta JA; Galindo-Rodríguez G; Vadillo-Buenfil M; Salazar-Exaire D
Ann Hematol; 2004 May; 83(5):295-301. PubMed ID: 15060749
[TBL] [Abstract][Full Text] [Related]
37. Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effect.
Huang XJ; Wang Y; Liu DH; Xu LP; Liu KY; Chen H; Chen YH; Han W; Shi HX
Bone Marrow Transplant; 2009 Sep; 44(5):309-16. PubMed ID: 19234512
[TBL] [Abstract][Full Text] [Related]
38. Gamma delta T cell reconstitution is associated with fewer infections and improved event-free survival after hematopoietic stem cell transplantation for pediatric leukemia.
Perko R; Kang G; Sunkara A; Leung W; Thomas PG; Dallas MH
Biol Blood Marrow Transplant; 2015 Jan; 21(1):130-6. PubMed ID: 25445640
[TBL] [Abstract][Full Text] [Related]
39. [Donor lymphocyte infusion for treatment of relapse of leukemia after HLA-mismatched hematopoietic stem cell transplantation].
Liu DH; Liu KY; Xu LP; Han W; Chen H; Chen YH; Zhang XH; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):78-82. PubMed ID: 18681305
[TBL] [Abstract][Full Text] [Related]
40. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation.
Russell NH; Byrne JL; Faulkner RD; Gilyead M; Das-Gupta EP; Haynes AP
Bone Marrow Transplant; 2005 Sep; 36(5):437-41. PubMed ID: 15980879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
